Brought to you by 
GSK licenses rights to Human Genome Sciences' Albugon
06 Aug 2021
Executive Summary
In its largest deal yet, Human Genome Sciences licensed GlaxoSmithKline exclusive worldwide development and commercialization rights to Albugon (albumin GLP-1) for all therapeutic and prophylactic applications.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK licenses rights to Human Genome Sciences' Albugon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice